# Mycobacteria for NEET PG Microbiology: Tuberculosis Under NTEP, Drug-Resistant TB, NTM and Leprosy (NLEP 2025)

Source: https://tracknation.in/story/mycobacteria-for-neet-pg-microbiology-tuberculosis-under-ntep-drug-resistant-tb-ntm-and-leprosy-nlep-2025 (TrackNation — free UPSC notes with PYQs)

> NEET PG Microbiology: mycobacterial cell wall, TB transmission and pathogenesis (Ghon, Ranke, reactivation), Xpert/Truenat, culture, TST/IGRA, NTEP 2HRZE/4HRE, RR/MDR/pre-XDR/XDR definitions and BPaLM, TB preventive treatment, MAC and other NTM, and leprosy classification, reactions and the 2025 NLEP regimen, with a diagram, hooks, MCQs and cards.

## Start Here

🎯 **Exam priority: Very high.** *Expect: droplet-nuclei spread, Ghon vs Ranke complex, latent reactivation risk, sites of
reactivation, Xpert/Truenat, liquid vs LJ culture times, TST/BCG, the NTEP DS-TB regimen and doses, the new DR-TB definitions (pre-XDR, XDR) and
BPaLM, TPT for contacts, NTM matching (MAC, marinum, ulcerans, scrofulaceum), and leprosy PB/MB criteria, MDT duration and reactions.*

CBME mapping: **MI7.3, MI5.4**. Fact-checked against the MSD Manual, the ICMR–NTEP DS-TB workflow (2022), NTEP DR-TB (2025) and TPT
(2021) guidelines, the India TB Report 2024 and NLEP (2025).

*TB, drug resistance, NTM and leprosy. Drawn by TrackNation.*

## The Organism and the Disease (MSD)

- Mycobacteria are **slow-growing aerobic bacilli** with a **mycolic-acid envelope** — acid-fast and poorly Gram-staining.
The **M. tuberculosis complex** includes M. tuberculosis, **M. bovis**, M. africanum and M. microti.

- Spread is by **droplet nuclei (1–5 µm)** from people with active pulmonary or laryngeal TB; **cavitary disease** is most
infectious. Primary and latent infection are usually not transmissible.

- **>90–95%** of primary infections are asymptomatic. A primary focus is a **Ghon focus**; with its node it is a **Ghon
complex**; calcified, a **Ranke complex**. **5 to <10%** of latent infections reactivate — favoured sites are the
**apical-posterior lung**, kidneys, epiphyses, vertebrae and meninges.

- Suspect TB with cough >2–3 weeks, haemoptysis, night sweats, weight loss. **HIV** is the strongest risk factor; presentations are
atypical. India 2023: **25.52 lakh** notified cases; estimated incidence **199 per lakh** (217 in 2015).

## Diagnosis (MSD, NTEP)

- **Smear** (ZN/auramine; needs ≥10,000 bacilli/mL — article 04), **NAATs** and **culture**.
**Xpert MTB/RIF (Ultra)** and **Truenat** detect M. tuberculosis DNA in about **2 hours** and **rifampicin
resistance**.

- Culture: **liquid media** are faster and more sensitive (2–3 weeks) than **Lowenstein–Jensen** (≥4 weeks); hold 8 weeks.
Liquid-culture DST guides DR-TB regimens.

- **Screening for infection**: tuberculin skin test or **IGRA**; BCG's effect on TST wanes after several years.

## Treatment and Prevention in India (NTEP)

*The NTEP drug-sensitive TB regimen 2HRZE/4HRE as a timeline. Drawn by TrackNation.*

- **DS-TB (ICMR–NTEP 2022)**: **2HRZE / 4HRE** daily weight-band FDCs — intensive phase 8 weeks (56 doses), continuation 16
weeks (112 doses), extended to 24 weeks for CNS and skeletal TB. Doses: **H 5, R 10, Z 25, E 15 mg/kg**; pyridoxine 10 mg/day.

- **Drug-resistance definitions (NTEP 2025)**: **RR-TB** — rifampicin resistance; **MDR-TB** — H + R;
**pre-XDR** — MDR/RR + any **fluoroquinolone**; **XDR** — MDR/RR + fluoroquinolone + **bedaquiline or linezolid**;
**Hr-TB** — isoniazid-resistant, rifampicin-sensitive.

- Regimens: **BPaLM** (bedaquiline, pretomanid, linezolid 600 mg, moxifloxacin 400 mg) for **6 months** (26 weeks, extendable)
in eligible patients; otherwise the **9–11-month** shorter oral or **18–20-month** longer oral regimen.

- **TPT (NTEP 2021)**: all **household contacts** of pulmonary TB, any age, after ruling out active TB; **under-5s need no
infection test**. Options include **6H** (daily isoniazid, 6 months), **3HP** (weekly rifapentine + isoniazid, 3 months);
**6Lfx** (levofloxacin, 6 months) for contacts of rifampicin-resistant, fluoroquinolone-sensitive TB; **4R** for contacts of isoniazid-resistant TB.

## NTM and Leprosy (MSD, NLEP)

- **NTM**: lungs commonest site; **MAC** (M. avium, M. intracellulare) causes most disease — prophylaxis in HIV with
**CD4 <50** when not suppressed; treated with a **macrolide + rifampicin/rifabutin + ethambutol**. **M. abscessus** can spread
between cystic-fibrosis patients. **M. marinum** — swimming-pool / **fish-tank granuloma**; **M. ulcerans** — **Buruli
ulcer** (grows at 32 °C over up to 12 weeks); child cervical lymphadenitis — MAC or **M. scrofulaceum**.

- **Leprosy** (M. leprae; M. lepromatosis since 2008): affinity for **peripheral nerves, skin and upper-airway mucosa**; spread by
**nasal droplets**, not casual contact; ~95% of exposed people never develop disease; peaks at 5–15 and >30 years; armadillos are a zoonotic
reservoir in the US.

- Spectrum: **tuberculoid** — strong cell-mediated immunity, few lesions (paucibacillary); **lepromatous** — weak CMI, widespread
bacilli (multibacillary). Reactions: **type 1 = reversal**; **type 2 = erythema nodosum leprosum** (immune complex), less common since
clofazimine.

- **NLEP (2023 classification, 2025 regimen)**: **PB = 1–5 lesions, no nerve, slit-skin smear negative**; **MB = >5 lesions,
nerve involvement, smear positive**. Both get **3-drug MDT** — rifampicin 600 mg monthly, clofazimine 300 mg monthly + 50 mg daily, dapsone
100 mg daily — **PB 6 months, MB 12 months**. Leprosy became **notifiable in 2025**; contacts get **single-dose rifampicin**.
Prevalence 0.57 per 10,000 (2024–25).

## Traps the Examiner Sets

- Ranke = calcified Ghon complex.

- Pre-XDR adds fluoroquinolone resistance; XDR adds bedaquiline or linezolid resistance too.

- India's NLEP now gives clofazimine to PB patients as well — 3 drugs for 6 months.

- Fish-tank granuloma is M. marinum; Buruli ulcer is M. ulcerans.

- Under-5 household contacts get TPT without a TST or IGRA once active TB is excluded.

## Memory Hooks & Shortcuts

*Shortcuts to lock in this article's numbers and lists. Each one only re-packages facts proven above.*

- 🧠 **'Ghon goes Gone-calcified = Ranke' — R for Rock-hard calcium** — TB pathology

- 🧠 **NTEP doses '5-10-25-15': H-R-Z-E mg/kg** — DS-TB

- 🧠 **Resistance ladder 'R → M → Pre → X': Rif, then H+R, then +FQ, then +Bdq/Lzd** — DR-TB

- 🧠 **'Fish Marinum, Buruli Ulcerans, Avium for AIDS'** — NTM

- 🧠 **'PB = Pretty Brief (6 months), MB = Much Bigger (12 months) — same 3 drugs now'** — leprosy

## Rapid-Revision Cards

- Acid-fast; poor Gram stain.

- M. tb, bovis, africanum, microti.

- Droplet nuclei 1–5 µm.

- Focus + node / calcified complex.

- 5 to <10%.

- Apical-posterior lung.

- DNA + rifampicin R in ~2 h.

- Liquid 2–3 wk; LJ ≥4 wk.

- 2HRZE / 4HRE; CP 24 wk for CNS, bone.

- H5 R10 Z25 E15 mg/kg.

- H + R.

- +FQ / +FQ + Bdq or Lzd.

- 6 months; Bdq, Pa, Lzd, Mfx.

- All HHC; <5 y no test; 6H, 3HP.

- Most NTM; HIV CD4 <50.

- Fish-tank granuloma.

- Buruli ulcer.

- Nerves, skin, nasal mucosa.

- 1–5, no nerve, SSS − / >5, nerve, SSS +.

- R + C + D: PB 6 mo, MB 12 mo.

- Type 1 reversal; type 2 ENL.

## Sources

*Facts in this article were checked against these documents.*

- MSD Manual Professional: Tuberculosis; Nontuberculous Mycobacterial Infections; Leprosy; Culture — Merck & Co. (MSD Manuals), 2024–26 (link)

- Standard Treatment Workflow: Drug-Sensitive TB Treatment as per NTEP — ICMR / Department of Health Research, 2022

- Guidelines for Programmatic Management of Drug-Resistant TB in India — Central TB Division, MoHFW, 2024–25

- Guidelines for Programmatic Management of TB Preventive Treatment in India — Central TB Division, MoHFW, 2021

- India TB Report 2024 — Central TB Division, MoHFW, 2024

- National Leprosy Eradication Programme — Directorate General of Health Services, MoHFW, 2025

- Competency Based Undergraduate Curriculum, Vol I: Microbiology (MI7.3, MI5.4) — National Medical Commission, 2024

## Test Yourself: Practice Questions

Thirty questions in NEET PG style, many of them programme and clinical scenarios.

## Practice Questions (NEET PG pattern)

*Original questions written in the style of the exam: +4 for a correct answer, −1 for a wrong one. Every answer
was checked against the sources listed above. NEET PG papers are not published by NBEMS, so these are not past-paper questions.*

**Q1.** Mycobacteria resist Gram staining and are acid-fast because of

- (a) mycolic acid in a lipid-rich envelope

- (b) spores

- (c) a thick capsule

- (d) lack of peptidoglycan

**Answer: (a)** — MSD.

**Q2.** The M. tuberculosis complex includes M. tuberculosis and

- (a) M. leprae

- (b) M. avium and M. intracellulare

- (c) M. bovis, M. africanum and M. microti

- (d) M. marinum

**Answer: (c)** — MSD.

**Q3.** TB is transmitted mainly by

- (a) droplet nuclei of 1–5 µm from people with active pulmonary TB

- (b) faeco-oral route

- (c) fomites

- (d) insect vectors

**Answer: (a)** — Cavitary disease most infectious.

**Q4.** A calcified primary focus with its calcified hilar node on chest X-ray is a

- (a) Simon focus

- (b) Ranke complex

- (c) Ghon focus

- (d) Assmann focus

**Answer: (b)** — Ghon complex when not calcified.

**Q5.** The proportion of latent TB infections that later reactivate is about

- (a) 50%

- (b) 5 to less than 10%

- (c) 90%

- (d) under 0.1%

**Answer: (b)** — Higher with HIV.

**Q6.** Reactivation pulmonary TB typically involves the

- (a) apical-posterior segments of the lung

- (b) middle lobe only

- (c) lingula

- (d) lower lobes

**Answer: (a)** — MSD.

**Q7.** The single most important factor predisposing to TB disease and death where both infections are common is

- (a) diabetes

- (b) HIV infection

- (c) alcohol

- (d) smoking

**Answer: (b)** — Atypical presentation.

**Q8.** Xpert MTB/RIF and Truenat tests detect M. tuberculosis DNA and

- (a) rifampicin resistance, in about 2 hours

- (b) all drug resistance

- (c) latent TB

- (d) isoniazid resistance only

**Answer: (a)** — MSD.

**Q9.** Compared with Lowenstein–Jensen medium, liquid culture for M. tuberculosis is

- (a) less sensitive

- (b) slower

- (c) not used

- (d) faster and more sensitive (2–3 weeks)

**Answer: (d)** — LJ ≥4 weeks.

**Q10.** TB infection is screened for with

- (a) sputum culture only

- (b) Widal

- (c) tuberculin skin test or interferon-gamma release assay

- (d) chest X-ray only

**Answer: (c)** — MSD.

**Q11.** The NTEP regimen for drug-sensitive TB is

- (a) 9HR

- (b) 2HRZE / 4HR thrice weekly

- (c) 6HRZE

- (d) 2HRZE / 4HRE

**Answer: (d)** — Daily FDCs.

**Q12.** In the NTEP DS-TB regimen, the drug stopped after the intensive phase is

- (a) pyrazinamide

- (b) rifampicin

- (c) isoniazid

- (d) ethambutol

**Answer: (a)** — ICMR–NTEP STW.

**Q13.** For TB meningitis and skeletal TB, NTEP extends the continuation phase to

- (a) 4 weeks

- (b) 52 weeks

- (c) 24 weeks

- (d) 8 weeks

**Answer: (c)** — ICMR–NTEP STW.

**Q14.** The daily dose of rifampicin in adult DS-TB (NTEP) is

- (a) 10 mg/kg

- (b) 25 mg/kg

- (c) 15 mg/kg

- (d) 5 mg/kg

**Answer: (a)** — H 5, Z 25, E 15.

**Q15.** MDR-TB is resistance to

- (a) isoniazid and rifampicin

- (b) ethambutol and pyrazinamide

- (c) rifampicin alone

- (d) any fluoroquinolone

**Answer: (a)** — NTEP.

**Q16.** Pre-XDR TB is MDR/RR-TB with additional resistance to

- (a) bedaquiline and linezolid

- (b) any fluoroquinolone

- (c) ethambutol

- (d) streptomycin

**Answer: (b)** — NTEP 2025.

**Q17.** XDR-TB (current definition) is MDR/RR-TB resistant to a fluoroquinolone and

- (a) bedaquiline or linezolid

- (b) an injectable aminoglycoside

- (c) pyrazinamide

- (d) isoniazid only

**Answer: (a)** — Group A drug.

**Q18.** The 6-month all-oral regimen prioritised for eligible MDR/RR-TB patients is

- (a) 2HRZE/4HRE

- (b) streptomycin-based

- (c) BPaLM

- (d) 18–20 month longer regimen

**Answer: (c)** — Bedaquiline, pretomanid, linezolid, moxifloxacin.

**Q19.** Under NTEP TPT guidelines, a 3-year-old household contact of a sputum-positive patient, with active TB excluded, should

- (a) receive TPT without TST or IGRA

- (b) receive full ATT

- (c) receive nothing

- (d) have IGRA first

**Answer: (a)** — NTEP 2021.

**Q20.** 3HP preventive therapy is

- (a) levofloxacin for 6 months

- (b) weekly rifapentine plus isoniazid for 3 months

- (c) daily isoniazid for 3 months

- (d) daily rifampicin for 4 months

**Answer: (b)** — NTEP.

**Q21.** Most non-tuberculous mycobacterial disease is due to

- (a) M. ulcerans

- (b) M. marinum

- (c) Mycobacterium avium complex

- (d) M. kansasii

**Answer: (c)** — M. avium + M. intracellulare.

**Q22.** A nodular ulcerating lesion on the hand of someone who cleans a home aquarium is due to

- (a) M. ulcerans

- (b) Mycobacterium marinum

- (c) M. leprae

- (d) Sporothrix

**Answer: (b)** — Fish-tank granuloma.

**Q23.** Buruli ulcer is caused by

- (a) M. abscessus

- (b) M. ulcerans

- (c) M. fortuitum

- (d) M. marinum

**Answer: (b)** — Grows at 32 °C.

**Q24.** In people with HIV not on effective ART, MAC prophylaxis is indicated when CD4 is below

- (a) 200 cells/µL

- (b) 500 cells/µL

- (c) 350 cells/µL

- (d) 50 cells/µL

**Answer: (d)** — MSD.

**Q25.** M. leprae shows special tropism for

- (a) peripheral nerves, skin and upper-airway mucosa

- (b) bone marrow

- (c) liver and spleen only

- (d) the CNS

**Answer: (a)** — MSD.

**Q26.** Leprosy is transmitted mainly through

- (a) insect bites

- (b) casual touch

- (c) blood transfusion

- (d) nasal droplets and secretions with prolonged contact

**Answer: (d)** — ~95% of exposed never get disease.

**Q27.** Under India's revised NLEP classification, a patient with 3 skin lesions, no nerve involvement and negative slit-skin smear has

- (a) multibacillary leprosy

- (b) indeterminate leprosy requiring no treatment

- (c) pure neural leprosy

- (d) paucibacillary leprosy

**Answer: (d)** — PB = 1–5, no nerve, smear negative.

**Q28.** The 2025 NLEP regimen for adult paucibacillary leprosy is

- (a) dapsone alone for 12 months

- (b) rifampicin and dapsone for 6 months

- (c) rifampicin, clofazimine and dapsone for 6 months

- (d) rifampicin, clofazimine and dapsone for 12 months

**Answer: (c)** — MB: 12 months.

**Q29.** Erythema nodosum leprosum is

- (a) a type 1 reversal reaction

- (b) a type IV skin test

- (c) a type 2 lepra reaction (immune complex)

- (d) a drug allergy to dapsone

**Answer: (c)** — Less common since clofazimine.

**Q30.** Contacts of a new leprosy patient in India receive

- (a) dapsone for 6 months

- (b) BCG revaccination only

- (c) single-dose rifampicin as post-exposure prophylaxis

- (d) nothing

**Answer: (c)** — Leprosy notifiable since 2025.

### Active Recall

From memory: describe the mycobacterial envelope and TB complex, how TB spreads and progresses (Ghon, Ranke, reactivation), the rapid tests and culture times, the NTEP DS-TB regimen and doses, the drug-resistance definitions and BPaLM, TB preventive treatment for contacts, the main NTM and their clues, and leprosy biology, classification, reactions and the 2025 NLEP regimen.
